Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1016/j.msard.2020.102402

http://scihub22266oqcxt.onion/10.1016/j.msard.2020.102402
suck pdf from google scholar
32711297!7366111!32711297
unlimited free pdf from europmc32711297    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32711297      Mult+Scler+Relat+Disord 2020 ; 45 (ä): 102402
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab #MMPMID32711297
  • Fernandez-Diaz E; Gracia-Gil J; Garcia-Garcia JG; Palao M; Romero-Sanchez CM; Segura T
  • Mult Scler Relat Disord 2020[Oct]; 45 (ä): 102402 PMID32711297show ga
  • BACKGROUND: Alemtuzumab is a treatment for highly active multiple sclerosis (MS). Immunosuppression is considered a risk factor for SARS-CoV-2 infection and there is still lack of evidence to guide MS practice. METHODS/RESULTS: We describe the clinical and immunological evolution of two MS patients under alemtuzumab treatment who were affected by COVID-19, one of them only one week after receiving her last dose, and both recovered without sequelae. CONCLUSION: In selected patients (young, without comorbidities, and with high activity), MS itself could be more dangerous than COVID-19, so we should consider continuing MS treatment as previously planned, including alemtuzumab.
  • |*Immunocompromised Host[MESH]
  • |Adult[MESH]
  • |Alemtuzumab/*therapeutic use[MESH]
  • |Antineoplastic Agents, Immunological/*therapeutic use[MESH]
  • |Betacoronavirus[MESH]
  • |COVID-19[MESH]
  • |Coronavirus Infections/*immunology[MESH]
  • |Female[MESH]
  • |Humans[MESH]
  • |Male[MESH]
  • |Multiple Sclerosis, Relapsing-Remitting/*drug therapy/*virology[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/*immunology[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box